Amneal Pharmaceuticals, Inc. (AMRX) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE.
Is Amneal Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
Amneal Pharmaceuticals, Inc. (AMRX) trades at 43.8× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $15 (-30 %).
Kaplio overview: Amneal Pharmaceuticals, Inc.
Market cap $7B · 52 weeks $10 – $21 (0 % below the high) · P/E 43.8× · 2027 expected P/E 17.7× · Dividend none · Next earnings November 3, 2026 · expected EPS $0.24 · Closing price, Oct 29 · accounts published Jul 30.
- Valuation: P/E 43.8× (expensive).
- Business: ROIC 13 % (fair).
- Balance sheet: Net debt/EBITDA 4.0× (fragile).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (30.4×) $15 (-30 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 6.2 %, fails.
- 5y EPS growth −17.8 %, fails.
- Gross margin 37.6 %, fails.
- Net debt / EBITDA 4.0×, fails.
- P/E vs own 10y history 43.8×, fails.
- FCF / Net Income 374.6 %, passes.
- ROIC 13.4 %, passes.
Against its peers (reference peers) — Amneal Pharmaceuticals, Inc.: P/E 43.8×; EV/EBITDA 14.5×; ROIC 13.4 %; $6.8B. Indivior Pharmaceuticals Inc (P/E 12.6×; EV/EBITDA 8.2×; ROIC 95.2 %; $4.4B), Dr. Reddy's Laboratories Limited (P/E 40.5×; EV/EBITDA 20.0×; ROIC 4.8 %; $11.0B), Bausch Health Companies Inc. (P/E —; EV/EBITDA 0.5×; ROIC 62.5 %; $3.3B).
Profitability
| Return on Equity | -326.75% |
| Return on Invested Capital | 13.38% |
| Return on Assets | 4.17% |
| Gross Margin | 39.32% |
| Operating Margin | 12.93% |
| Net Margin | 5.05% |
Financial Health
| Debt / Equity | 84.54 |
| Current Ratio | 2.20 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.98 |
Price Performance
| 1 month | +6.01% |
| 3 months | +16.54% |
| Year-to-date | +69.44% |
| 1 year | +113.50% |
| 3 years | +451.68% |
| 5 years | +288.89% |
| 10 years | +1.91% |
Related companies: TEVA · VTRS · INDV · RDY · BHC · PRGO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of AMRX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks